Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) saw a significant decrease in short interest in February. As of February 13th, there was short interest totaling 56,472 shares, a decrease of 20.8% from the January 29th total of 71,276 shares. Approximately 3.3% of the company’s stock are short sold. Based on an average daily volume of 31,172 shares, the short-interest ratio is currently 1.8 days. Based on an average daily volume of 31,172 shares, the short-interest ratio is currently 1.8 days. Approximately 3.3% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Cadrenal Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $32.00.

Insider Activity at Cadrenal Therapeutics

In other Cadrenal Therapeutics news, CFO Matthew K. Szot sold 9,933 shares of Cadrenal Therapeutics stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $6.97, for a total transaction of $69,233.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 26.09% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cadrenal Therapeutics

A number of hedge funds have recently bought and sold shares of CVKD. DRW Securities LLC bought a new position in shares of Cadrenal Therapeutics in the fourth quarter worth about $171,000. Geode Capital Management LLC grew its holdings in Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Cadrenal Therapeutics in the 3rd quarter valued at approximately $103,000. Finally, Citadel Advisors LLC bought a new position in Cadrenal Therapeutics in the 3rd quarter worth approximately $274,000. 7.92% of the stock is currently owned by institutional investors.

Cadrenal Therapeutics Stock Up 1.3%

NASDAQ:CVKD opened at $8.49 on Monday. The company’s 50 day moving average is $7.04 and its 200-day moving average is $10.45. Cadrenal Therapeutics has a 12 month low of $4.91 and a 12 month high of $20.39. The firm has a market cap of $19.87 million, a price-to-earnings ratio of -1.06 and a beta of 1.03.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.